Dr. Jin Wang is currently an Associate Professor in the Department of Breast Oncology at SYSUCC. She specializes in breast oncology and is a renowned young oncological surgeon in China. Dr. Jin Wang graduated from Peking Union Medical College and obtained M.D. degree in 2012, and then worked as a surgeon at SYSUCC. From 2019 to 2020, Dr. Jin Wang had been a Postdoctoral Fellow in the Department of Surgical Oncology, Massachusetts General Hospital, Harvard University. Dr. Jin Wang serves as a Youth Committee member in multiple academic associations (e.g. Chinese Society of Clinical Oncology, Guangdong Medical Association). She also has passionate in medical teaching and has been awarded as “2018 Outstanding Teachers of Surgical Residency Training”. Dr. Jin Wang is awarded as “Most Promising Young Oncologists (2017 CSCO)”.

Clinical Research: 1) Breast plastic and reconstructive surgery; 2) Laparoscopic breast cancer surgery; 3) Immunotherapy for breast cancer; 40 Targeted therapy for breast cancer.

Basic and Translational Research: 1) Mechanism of the growth and metastasis of breast cancer; 2) Sensitive biomarkers for immunotherapy of breast cancer; 3) Nanoparticle biotechnology; 4) Application of AI in diagnosis and treatment of breast cancer.

2019-2020
Postdoctoral Fellow, Department of Surgical Oncology, Massachusetts General Hospital, Harvard University

2009-2012
M.D. Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

2002-2009
M.M. 7-Year-Program Clinical Medicine, Harbin Medical University

Selected publications
1. Wang Z#, Yang L#, Wu P#, Li X#, Tang Y, Ou X, Zhang Y, Xiao X, Wang J*, Tang H*. The circROBO1/KLF5/FUS feedback loop regulates the liver metastasis of breast cancer by inhibiting the selective autophagy of afadin. Mol Cancer. 2022 Jan 24;21(1):29.

2. Wang J#*, Tang H#, Yin K#, Li X, Xie X, Hughes KS*. Second invasive breast cancers in patients treated with breast-conserving therapy. Eur J Surg Oncol. 2021 Oct;47(10):2492-2498.

3. Wang J*, Singh P, Yin K, Zhou J, Bao Y, Wu M, Pathak K, McKinley SK, Braun D, Hughes KS*. Disease Spectrum of Breast Cancer Susceptibility Genes. Front Oncol. 2021;11:663419.

4. Wang J#*, Tang H#, Li X, Song C, Xiong Z, Wang X, Xie X, Tang J*. Is surgical axillary staging necessary in women with T1 breast cancer who are treated with breast-conserving therapy? Cancer Commun. 2019;39(1):25.

5. Tang H#, Huang X#, Wang J#, Yang L, Kong Y, Gao G, Zhang L, Chen ZS, Xie X*. circKIF4A acts as a prognostic factor and mediator to regulate the progression of triple-negative breast cancer. Mol Cancer. 2019;18(1):23.

6. Wang J#*, Song C#, Tang H#, Zhang C, Tang J, Li X, Chen B, Xie X*. miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer. Breast Cancer Res. 2017;19(1):72.

7. Chen B#, Wang J#, Dai D#, Zhou Q, Guo X, Tian Z, Huang X, Yang L, Tang H, Xie X*. AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer. J Exp Clin Cancer Res. 2017;36(1):65.

8. Wang J#*, Zhang C#, Tang H#, Tang H, Tang J, Song C, Xie X*. ERβ1 inversely correlates with PTEN/PI3K/AKT pathway and predicts a favorable prognosis in triple-negative breast cancer. Breast Cancer Res Treat. 2015;152:255-269.

9. Wang J*, Xiaoming Xie*, Xi Wang, Tang J, Pan Q, Zhang Y, Di M. Locoregional and distant recurrences after breast conserving therapy in patients with triple-negative breast cancer: a meta-analysis. Surg Oncol. 2013;22:247-255.

10. Wang J*, Yu JC*, Kang WM, Liu YQ, Meng QB, Cao ZJ. The predictive effect of cadherin-17 on lymph node micrometastasis in pN0 gastric cancer. Ann Surg Oncol. 2012;19(5):1529-1534.

Updated June 2022